乳腺良、恶性病变组织中Livin和Smac的表达

Expressions of Livin and Smac in benign and malignant breast lesions

目的:观察乳腺良、恶性病变组织中Smac和凋亡蛋白抑制因子家族成员Livin的表达情况。方法:选取乳腺良性增生及乳腺导管癌组织共152例(乳腺良性增生41例,乳腺导管内癌20例,乳腺浸润性导管癌91例;有淋巴结转移61例,无淋巴结转移30例),对照癌组织HE切片,选择富有肿瘤细胞且无出血坏死的区域,手工制备82点阵和70点阵的组织芯片2片。另取18例手术远端正常乳腺组织常规切片作对照。采用免疫组织化学SP法检测上述组织中Livin和Smac蛋白的表达情况。结果:①正常乳腺、乳腺良性增生、乳腺导管内癌和乳腺浸润性导管癌组织中Livin蛋白阳性率分别为11.1%(2/18)、43.9%(18/41)、80.0%(16/20)和90.1%(82/91),差异具有统计学意义(χ2=60.800,P<0.05)。Livin蛋白阳性率与乳腺浸润性导管癌患者的年龄、肿瘤大小、淋巴结转移、TNM分期、ER、PR无关(P均>0.05)。②正常乳腺、乳腺良性增生、乳腺导管内癌和乳腺浸润性导管癌组织中Smac蛋白阳性率分别为83.3%(15/18)、78.0%(32/41)、90.0%(18/20)和50.5%(46/91),差异有统计学意义(χ2=19.646,P<0.05)。Smac蛋白阳性率与乳腺浸润性导管癌患者的年龄、肿瘤大小、ER、PR无关(P均>0.05),与淋巴结转移有关(χ2=32.772,P<0.05)。结论:Livin及Smac蛋白的异常可能在乳腺癌的发生与演进中起重要作用。

Aim：To investigate the expressions of Livin and Smac in breast benign and malignant lesions.Methods：A total of 152 samples including 18 cases of invasive breast distal normal breast tissue,41 cases of benign breast hyperplasia,20 cases of intraductal breast cancer,91 cases with breast ductal carcinoma（61 cases with lymph node metastasis,30 cases without lymph node metastasis） were collected to detect Livin and Smac proteins using immunohistochemical method and tissue microarrays analysis.Results：①The positive rates of Livin protein in normal tissue, benign breast hyperplasia, intradactal breast cancer and breast ductal carcinoma tissue were 11. 1% （2/18） , 43.9% （18/41） , 80.0% （16/20） , and 90.1% （ 82/91 ） , respectively increased by turn （χ2 = 60. 800, P 〈 0.05 ）. The positive rates of Smae protein in tissues mentioned above were 83.3% （15/18） , 78.0% （32/41） ,90.0% （18/20） ,and 50.5% （46/91） ,respectively. There were significantly differences in the positive rate of Smac in the 4 groups（χ2 = 19. 646 ,P 〈 O. 05 ）. Smac expression was not correlated with patient＇ s age, the size of the tumor, ER, and PR （ P 〉 0.05 ） , but correlated with lymph node metastasis （χ2 = 32. 772,P 〈 0.05 ）. Conclusion： Livin and Smac might play an important role in the carcinogenesis and progression in breast carcinoma.